Eli Lilly And Company (LLY): Today's Featured Drugs Winner

Eli Lilly and Company ( LLY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.7%. By the end of trading, Eli Lilly and Company rose 43 cents (1.1%) to $41.31 on light volume. Throughout the day, 4.7 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 6.5 million shares. The stock ranged in a price between $41.07-$41.43 after having opened the day at $41.10 as compared to the previous trading day's close of $40.88. Other companies within the Drugs industry that increased today were: Arena Pharmaceuticals ( ARNA), up 21.9%, Abaxis ( ABAX), up 20.9%, Jazz Pharmaceuticals ( JAZZ), up 14.4%, and China Shenghuo Pharmaceutical Holdings ( KUN), up 13.4%.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $47.34 billion and is part of the health care sector. The company has a P/E ratio of 11.4, above the average drugs industry P/E ratio of 10.5 and below the S&P 500 P/E ratio of 17.7. Shares are down 1.6% year to date as of the close of trading on Thursday. Currently there are three analysts that rate Eli Lilly and Company a buy, two analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share.

On the negative front, POZEN ( POZN), down 19.3%, InterMune ( ITMN), down 17.1%, Medgenics ( MDGN), down 12.6%, and Galena Biopharma ( GALE), down 8.3%, were all losers within the drugs industry with Gilead ( GILD) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens